Trial Search Results
OPsumit USers Registry
Prospective observational drug registry developed to characterize the safety profile (including primarily potential serious hepatic risks) and to describe clinical characteristics and outcomes of patients newly treated with Opsumit in the post-marketing setting.
Stanford is currently accepting patients for this trial.
- Drug: Opsumit (macitentan)
Patients newly treated with Opsumit defined as a new user of therapy, initiated ≤ 30 days
prior to enrollment visit.
Previous user of Opsumit defined as patient who initiated therapy >30 days prior to
Patients enrolled in any ongoing clinical trials
Ages Eligible for Study
N/A - N/A
Genders Eligible for Study